Can cause fetal harm. Advise patients of reproductive potential of the potential risk to a fetus and to use effective contraception. Advise not to breastfeed during treatment. May impair male fertility.
- TRADE NAME: Inqovi (Otsuka)
- INDICATIONS: Myelodysplastic syndromes
- CLASS: Cytidine deaminase inhibitor (cedazuridine), Nucleoside metabolic inhibitor (decitabine)
- HALF-LIFE: 1.5 hours (decitabine); 6.7 hours (cedazuridine)
- FDA APPROVAL DATE: 07/07/2020
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
drugs metabolized by cytidine deaminase - PREGNANCY: Can cause fetal harm when administered to a pregnant woman.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
